ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)

Q: What does CUSIP H0036K147 represent in this 13F holders report?

CUSIP H0036K147 is the security identifier for ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share used to aggregate holder disclosures.

Q: How many institutions held ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in Q2 2020?

41 institutional investors reported ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share for Q2 2020. Use the holders table for investor-level position and value details.

CUSIP: H0036K147

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class: Equity / Common Shares, par value CHF 0.08 per share
Shares outstanding: 128,210,515
Total 13F shares: 21,557,623
Share change: +21,557,623
Total reported value: $1,000,339,109
Price per share: $46.81
Number of holders: 41
Value change: +$1,000,339,111
Number of buys: 41

Quarterly Holders Quick Answers

What is CUSIP H0036K147?
CUSIP H0036K147 identifies ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2020

Recent filing periods for CUSIP H0036K147:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q2 2020

As of 30 Jun 2020, ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by 41 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 21,557,623 shares. The largest 10 holders included Redmile Group, LLC, FMR LLC, BAKER BROS. ADVISORS LP, Magnetar Financial LLC, Grosvenor Holdings, L.L.C., JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., PRICE T ROWE ASSOCIATES INC /MD/, MPM Oncology Impact Management LP, and HILLHOUSE CAPITAL ADVISORS, LTD.. This page lists 41 institutional shareholders reporting positions in this security for the Q2 2020 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2020 vs Q4 2025 Across Filers

Q4 2025 holders

114

Q2 2020 holders

Holder diff

-73

Investor	Q4 2025 Shares	Q2 2020 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q2 2020 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.